Dimachkie, M., Barohn, R., Byrne, B., Goker-Alpan, O., Kishnani, P., Ladha, S., … Schoser, B. (2020). NEO1 and NEO-EXT Studies: Long-Term Safety and Exploratory Efficacy of Repeat Avalglucosidase Alfa Dosing for 5.5 Years in Late-Onset Pompe Disease Patients. In NEUROLOGY (Vol. 94).

Dimachkie, Mazen, Richard Barohn, Barry Byrne, Ozlem Goker-Alpan, Priya Kishnani, Shafeeq Ladha, Pascal Laforet, et al. “NEO1 and NEO-EXT Studies: Long-Term Safety and Exploratory Efficacy of Repeat Avalglucosidase Alfa Dosing for 5.5 Years in Late-Onset Pompe Disease Patients.” In NEUROLOGY, Vol. 94, 2020.

Dimachkie M, Barohn R, Byrne B, Goker-Alpan O, Kishnani P, Ladha S, et al. NEO1 and NEO-EXT Studies: Long-Term Safety and Exploratory Efficacy of Repeat Avalglucosidase Alfa Dosing for 5.5 Years in Late-Onset Pompe Disease Patients. In: NEUROLOGY. 2020.

Dimachkie, Mazen, et al. “NEO1 and NEO-EXT Studies: Long-Term Safety and Exploratory Efficacy of Repeat Avalglucosidase Alfa Dosing for 5.5 Years in Late-Onset Pompe Disease Patients.” NEUROLOGY, vol. 94, no. 15, 2020.

Dimachkie M, Barohn R, Byrne B, Goker-Alpan O, Kishnani P, Ladha S, Laforet P, Mengel KE, Pena L, Sacconi S, Straub V, Trivedi J, Van Damme P, van der Ploeg A, Vissing J, Young P, Haack KA, Fleurinck C, Johnson J, Liu K, Schoser B. NEO1 and NEO-EXT Studies: Long-Term Safety and Exploratory Efficacy of Repeat Avalglucosidase Alfa Dosing for 5.5 Years in Late-Onset Pompe Disease Patients. NEUROLOGY. 2020.